INTRODUCTION AND OBJECTIVES: Since the United States
Preventative Services Task Force (USPSTF) recommendations against routine prostatic specific antigen (PSA) screening in 2012, PSA testing has declined significantly. We hypothesized that prostate biopsy incidence would mimic this pattern. We characterized trends from 2012-2014, and described factors associated with geographic variation in biopsy use.
METHODS: Using Medicare Provider Utilization and Payment data (2012) (2013) (2014) , we captured reimbursements for prostate biopsies (i.e., CPT 55700) performed by physicians performing 10 annual biopsies. We calculated annual incidence (i.e., number of biopsies per 1,000 eligible men) across 306 hospital referral regions (HRR). HRRlevel factors of interest included % men 75 years of age with PSA screening in 2012, % African-Americans, provider density, average hierarchical condition category (HCC) index (for Medicare risk adjustment), and number of male beneficiaries. Multivariable regression adjusted for factors associated with annual incidence of prostate biopsy, and predicted prostate biopsy incidence ratios were generated across all HRRs.
RESULTS: Overall, we identified 359,698 biopsies performed by physicians, and the annual incidence ratio decreased from 10.95 biopsies/1,000 men in 2012 to 8.74 biopsies/1,000 men in 2014 (p<0.001). In 2014, the strongest associations with incidence of prostate biopsy were seen with % PSA screening (b¼+2.25 per 10% screened, p<0.001) and biopsy provider density (b¼+2.00 per provider per 1,000 men, p<0.001). There was also a significant associations seen with % African-American population (b¼+0.47 per 10% increase, p¼0.017) and inverse association with average HCC score (b¼-0.07 per 0.01 increase, p¼0.006). At the HRR-level in 2014, we noted nearly 40-fold variation across 306 HRRs, from predicted 0.75 to 19.51 biopsies per 1,000 eligible men ( Figure, p<0 .001) CONCLUSIONS: The incidence of prostate biopsies has decreased in parallel to drops in PSA screening and prostate cancer incidence after 2012. PSA screening and provider density were strongly associated with prostate biopsy incidence, and unmeasured patient and provider-level factors are likely driving considerable geographic variation in the use of prostate biopsy.
Source of Funding: Emory Urology Research Scholars Grant; Winship Cancer Institute Prostate Cancer Pilot Grant

MP76-02 UROLOGIST PRACTICE AFFILIATION AND INTENSITY MODULATED RADIATION THERAPY FOR PROSTATE CANCER
Lindsey Herrel*, Brent Hollenbeck, Samuel Kaufman, Phyllis Yan, Tudor Borza, Ann Arbor, MI; Florian Schroeck, Hanover, NH; Bruce Jacobs, Pittsburgh, PA; Ted Skolarus, Vahakn Shahinian, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: Prostate cancer treatment is a significant source of morbidity and spending. It is widely believed that some men with prostate cancer, particularly those with significant health problems, are unlikely to benefit from treatment. Financial incentives associated with urologist ownership of radiation facilities have the potential to spur utilization despite this understanding about disease biology.
METHODS: Using a 20% sample of national Medicare claims between 2010 and 2013, prostate cancer treatment was measured according to urologist practice affiliation (i.e., single specialty groups by size, multispecialty group). Overall treatment, and intensity modulated radiation therapy (IMRT) in particular, was further assessed by urologist ownership of IMRT and patient risk of non-cancer mortality within 10 years of diagnosis. Generalized estimating equations were used to adjust for patient differences.
RESULTS: Among the men with newly diagnosed prostate cancer, use of IMRT ranged from 23.5% in multispecialty groups to 37.4% in large urology groups (p < 0.001). In the cohort, 5,133 patients were managed in urology groups with IMRT ownership. Urologists with ownership interest were more likely to use IMRT compared with nonowners practicing in single specialty groups (42.5% vs. 29.5%, p < 0.001), regardless of group size. Among patients with a very high risk ( 75%) of non-cancer death within 10 years of diagnosis, both IMRT use (41.6% vs. 26.3%, p < 0.001) and overall treatment with curative intent (52.7% vs. 43.5%, p < 0.001, Figure) were more likely in urology groups with ownership compared with non-owners, respectively.
CONCLUSIONS: Urologists practicing in single-specialty groups with an ownership interest in radiation therapy are more likely to treat men with prostate cancer, including those with a high risk of noncancer mortality. 
MP76-03 SMALL EFFECT OF PHARMACEUTICAL INDUSTRY PAYMENTS TO PHYSICIANS ON MEDICARE PRESCRIPTION HABITS: USING ABIRATERONE AND ENZALUTAMIDE
Omar Ayyash*, Jathin Bandari, Robert Turner, Bruce Jacobs, Benjamin Davies, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Abiraterone and enzalutamide are both oral chemotherapeutic agents used in metastatic prostate cancer that have been aggressively marketed to physicians since FDA approval in 2011 and 2012, respectively. We sought to investigate if there is an association between pharmaceutical industry payments to physicians and prescriptions for abiraterone and enzalutamide.
METHODS: Using the Open Payments Database from 2014, we determined the number and total dollar amount of payments from industry to each urologist or oncologist who prescribed abiraterone and enzalutamide. These data were merged with the 2013 Medicare Part D Provider and Utilization Data to identify the total claim count ascribed to each physician as well as the total drug cost per prescribing physician. Drug costs (primary outcome) and claim counts (secondary outcome) were compared between prescribers who did and did not receive industry payment using Wilcoxon rank-sum tests. A Spearman Rank correlation was used to assess the relationship between industry payments and total drug costs/total claim counts for each drug.
RESULTS: For abiraterone, we identified 4918 Open Payment recipients and 1197 prescribers, of whom 615 were both recipients and prescribers. The median payment amount to prescribers was $72 . For enzalutamide, we identified 7820 Open Payment recipients and 412 prescribers, of whom 289 were both recipients and prescribers. The median payment amount to prescribers was 59$ (IQR $25-$148). There was no statistical association between industry payment amount and total drug costs among abiraterone prescribers (r ¼ 0.07, p ¼ 0.11) and there was a small association among enzalutamide prescribers (r ¼ 0.33, p < 0.001) (Figure) .
CONCLUSIONS: Industry payments to prescribers of abiraterone and enzalutamide were common but of low amount. There was a small association between total drug costs and industry payments for prescribers of enzalutamide, but not abiraterone. Continued public reporting of industry payments to physicians will allow for further investigation of this relationship. METHODS: The publicly available www.clinicaltrials.gov website was individually queried for new trials first received between 2006 and 2015 for the following search terms: "prostate cancer," "kidney cancer" and "bladder cancer." Each category was then stratified by funder type including: NIH, Industry, Other Federal Agency and all others (individuals, universities, organizations.) Trends in funding sources across the decade were examined. RESULTS: Newly registered clinical trials from 2006 to 2015 included 2,487 prostate, 901 kidney and 517 bladder trials, with an upward trend in overall, prostate and bladder trials across the decade. Figure 1 reflects the distribution among cancer type. For all three malignancies, the absolute number of NIH-funded trials decreased while industry funded trials increased when comparing 2006 to 2015. Prostate cancer: NIH: 52 / 36, Industry: 67 / 83 (p¼0.043) Kidney cancer: NIH: 37 / 15, Industry: 28 / 38 (p¼0.002) Bladder cancer: NIH 15 / 10, Industry 12 / 39 (p¼0.002). Similarly, the percentage of NIH funded trials showed a progressive decrease across the decade for all three malignancies. Trials run by 0 other 0 organizations including individuals, universities and organizations displayed the most growth comprising 13-27% of studies in 2006 compared to 43-57% of trials in 2015. Percentage distribution by funder type for each malignancy is reflected in Figure 2 .
CONCLUSIONS: The funding of new trials for prostate, kidney and bladder cancer have each exhibited a progressive, sustained decrease in federally-funded trials across the last decade, while there has been in an increase in industry funded trials. It is critical to consider the sources of funding for clinical trials, and strive for balanced distribution of research funds.
